UK Government Confirms Indefinite Recognition of CE Marked Medical Devices

• The UK government confirmed on October 21, 2026, that CE marked medical devices will be indefinitely accepted in Great Britain.
• This decision ensures continued patient access to essential medical technologies already approved for the EU market.
• The policy avoids duplicate approval processes for manufacturers and supports stable supply.
• The UKCA marking route remains the domestic approval pathway, undergoing modernization alongside plans for a future licensing framework.
• The move aligns with broader government strategies to secure supply, foster innovation, and reduce regulatory burden.

By providing a clear and predictable regulatory framework, the government aims to secure the supply of medical devices for UK patients while simultaneously fostering safe and rapid access to new innovations, ensuring patients can benefit from the latest technological advancements.

The UK government announced on October 21, 2026, its decision to indefinitely accept medical devices bearing the CE mark, ensuring their continued availability in Great Britain. This crucial confirmation applies specifically to medical devices and in vitro diagnostic devices (IVDs) that have already secured approval for the European Union market. The move is designed to guarantee that patients across Great Britain retain access to a wide array of vital medical technologies, ranging from essential insulin pumps and replacement joints to critical diagnostic tests and surgical equipment.

This significant policy direction emerged following a comprehensive public consultation process. The consultation, which ran from February 16, 2026, to April 10, 2026, garnered substantial feedback, receiving more than 1,000 responses. These contributions came from a diverse group of stakeholders, including patients, various healthcare organizations, and industry representatives, all of whom provided valuable input that informed the government's final determination.

The decision to continue recognizing CE marked devices is particularly impactful given their widespread use; currently, over 90% of medical devices registered for use in Great Britain carry this European approval. This recognition means that manufacturers will not be required to navigate an additional, separate approval pathway for devices already cleared for the EU market, thereby preventing unnecessary duplication of effort. While the CE mark recognition continues, the UK's domestic approval pathway, known as the UKCA marking route, remains fully operational for devices introduced to the Great British market.

The Medicines and Healthcare products Regulatory Agency (MHRA) retains its overarching responsibility for all medical devices within the UK market. This includes rigorous safety monitoring, facilitated by mechanisms such as the Yellow Card scheme, and active collaboration with international partners to exchange critical safety information. These robust oversight measures empower the MHRA to intervene and safeguard patients whenever necessary. Furthermore, the UKCA route itself is undergoing modernization through a pre-market statutory instrument, which will update the specific requirements devices must satisfy to achieve UKCA marking. In parallel, the government intends to pursue primary legislation to establish a future licensing approach for medical devices, aiming for a more agile and contemporary framework capable of adapting to rapidly advancing medical technologies, including sophisticated software and AI-driven medical devices. This forward-looking approach is informed by recommendations from the National Commission into the Regulation of AI in Healthcare.

The government's commitment to indefinitely recognize CE marked medical devices carries substantial benefits, primarily by helping to maintain a stable supply of medical technologies and ensuring uninterrupted patient access. This regulatory clarity is vital for both patients and the National Health Service (NHS), which relies heavily on these treatments and innovations. By providing a clear and predictable regulatory framework, the government aims to secure the supply of medical devices for UK patients while simultaneously fostering safe and rapid access to new innovations, ensuring patients can benefit from the latest technological advancements.

This strategic direction aligns seamlessly with broader governmental ambitions, including those outlined in the Life Sciences Sector Plan and the 10 Year Health Plan, which emphasize the development and availability of new health technologies. Moreover, the continued recognition of CE-marked devices is consistent with the MHRA’s 2030 Strategy. This strategy seeks to expand reliance and recognition routes with trusted international regulators, a move designed to alleviate regulatory burdens, bolster supply chain resilience, and ultimately facilitate timely patient access to essential medical care.

Source: Original reporting via GOV.UK press release.